Joseph W. LaPlume
Known title: EVP, Corp Strategy & DevelopCIK: 0001767215
Joseph W. LaPlume's purchase track record
Joseph W. LaPlume has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/3/2026 | CRL | $4K | -0.5% | +60.7% | +11.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CRL | ▼ Sell | Gift | 257 | $0 | 8/10/2026 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 235 | $42K | 5/31/2026 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 744 | $134K | 5/30/2026 | View on chart |
| CRL | ▲ Buy | Grant | 5,257 | $950K | 5/29/2026 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 185 | $29K | 5/27/2026 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 243 | $39K | 5/26/2026 | View on chart |
| CRL | ▲ Buy | Open Market | 25 | $4K | 3/3/2026 | View on chart |
| CRL | ▲ Buy | Grant | 5,456 | $0 | 1/30/2026 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 1,749 | $370K | 1/30/2026 | View on chart |
| CRL | ▼ Sell | Open Market | 400 | $65K | 8/22/2025 | View on chart |
| CRL | ▼ Sell | Open Market | 800 | $126K | 8/18/2025 | View on chart |
| CRL | ▼ Sell | Open Market | 400 | $60K | 8/7/2025 | View on chart |
| CRL | ▼ Sell | Gift | 385 | $0 | 6/5/2025 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 155 | $21K | 5/31/2025 | View on chart |
| CRL | ▲ Buy | Grant | 6,709 | $910K | 5/30/2025 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 83 | $12K | 5/28/2025 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 122 | $17K | 5/27/2025 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 161 | $22K | 5/26/2025 | View on chart |
| CRL | ▼ Sell | Open Market | 500 | $73K | 5/13/2025 | View on chart |
| CRL | ▼ Sell | Open Market | 4,400 | $715K | 2/20/2025 | View on chart |
| CRL | ▲ Buy | Grant | 2,738 | $0 | 1/31/2025 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 846 | $140K | 1/31/2025 | View on chart |
| CRL | ▼ Sell | Open Market | 1,780 | $355K | 8/8/2024 | View on chart |
| CRL | ▼ Sell | Gift | 311 | $0 | 6/3/2024 | View on chart |
| CRL | ▲ Buy | Grant | 2,111 | $0 | 5/31/2024 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 223 | $48K | 5/29/2024 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 125 | $27K | 5/28/2024 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 184 | $40K | 5/27/2024 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 243 | $53K | 5/26/2024 | View on chart |
| CRL | ▼ Sell | Open Market | 1,304 | $296K | 5/10/2024 | View on chart |
| CRL | ▼ Sell | Open Market | 838 | $200K | 2/15/2024 | View on chart |
| CRL | ▲ Buy | Grant | 3,350 | $0 | 1/29/2024 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 1,025 | $226K | 1/29/2024 | View on chart |
| CRL | ▼ Sell | Open Market | 1,850 | $366K | 11/30/2023 | View on chart |
| CRL | ▲ Buy | Option Exercise | 9,128 | $1.3M | 11/9/2023 | View on chart |
| CRL | ▼ Sell | Open Market | 2,585 | $447K | 11/9/2023 | View on chart |
| CRL | ▼ Sell | Open Market | 6,543 | $1.1M | 11/9/2023 | View on chart |
| CRL | ▼ Sell | Open Market | 700 | $152K | 8/10/2023 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 223 | $43K | 5/29/2023 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 125 | $24K | 5/28/2023 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 184 | $36K | 5/27/2023 | View on chart |
| CRL | ▲ Buy | Grant | 2,189 | $0 | 5/26/2023 | View on chart |
| CRL | ▼ Sell | Open Market | 345 | $66K | 5/15/2023 | View on chart |
| CRL | ▼ Sell | Open Market | 950 | $183K | 5/12/2023 | View on chart |
| CRL | ▼ Sell | Open Market | 9 | $2K | 5/12/2023 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 317 | $77K | 2/22/2023 | View on chart |
| CRL | ▲ Buy | Grant | 8,676 | $0 | 1/27/2023 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 3,261 | $797K | 1/27/2023 | View on chart |
| CRL | ▲ Buy | Option Exercise | 6,409 | $701K | 12/1/2022 | View on chart |
| CRL | ▼ Sell | Open Market | 1,138 | $254K | 12/1/2022 | View on chart |
| CRL | ▼ Sell | Open Market | 4,165 | $935K | 12/1/2022 | View on chart |
| CRL | ▼ Sell | Open Market | 1,106 | $249K | 12/1/2022 | View on chart |
| CRL | ▼ Sell | Open Market | 534 | $116K | 11/4/2022 | View on chart |
| CRL | ▼ Sell | Open Market | 200 | $45K | 8/5/2022 | View on chart |
| CRL | ▼ Sell | Gift | 195 | $0 | 7/6/2022 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 223 | $55K | 5/29/2022 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 125 | $31K | 5/28/2022 | View on chart |
| CRL | ▲ Buy | Grant | 1,657 | $0 | 5/27/2022 | View on chart |
| CRL | ▼ Sell | Open Market | 395 | $116K | 2/23/2022 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 315 | $91K | 2/23/2022 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 317 | $93K | 2/22/2022 | View on chart |
| CRL | ▼ Sell | Open Market | 4 | $1K | 2/22/2022 | View on chart |
| CRL | ▼ Sell | Open Market | 392 | $114K | 2/22/2022 | View on chart |
| CRL | ▲ Buy | Option Exercise | 743 | $65K | 2/18/2022 | View on chart |
| CRL | ▼ Sell | Open Market | 1,143 | $334K | 2/18/2022 | View on chart |
| CRL | ▼ Sell | Gift | 150 | $0 | 2/14/2022 | View on chart |
| CRL | ▲ Buy | Grant | 11,344 | $0 | 1/28/2022 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 4,570 | $1.4M | 1/28/2022 | View on chart |
| CRL | ▲ Buy | Grant | 6,771 | $0 | 12/25/2021 | View on chart |
| CRL | ▼ Sell | Gift | 182 | $0 | 11/22/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
CRL Analyst Targets Rise After UBS Reinstates Coverage
Charles River Laboratories saw its average analyst price target increase to $305.00, driven by UBS reinstating coverage with a $357.00 target. This move follows reports of stabilizing demand and increased interest in animal model markets. The stock is currently trading below its 52-week high, with technical indicators showing support near $181.76.
CRL Analyst Targets Rise After UBS Reinstates Coverage. Charles River Laboratories saw its average analyst price target increase to $305.00, driven by UBS reinstating coverage with a $357.00 target. This move follows reports of stabilizing demand and increased interest in animal model markets. The stock is currently trading below its 52-week high, with technical indicators showing support near $181.76.